Olanzapine and valproate semisodium in the treatment of acute mania associated with bipolar I disorder
By: National Institute for Clinical Excellence.
Contributors: National Institute for Clinical Excellence.
Series: Technology appraisal -- 66
Publisher: National Institute for Clinical Excellence
Published: 2003
Place of publication: London
Language: eng
Number of pages: 26
Notes: At the date of issue of this guidance, within the classes of agents referred to the Institute by the Department of Health and the Welsh Assembly Government only olanzapine and valproate semisodium held a marketing authorisation for the treatment of acutemania in bipolar I disorder.